osimertinib
astrazeneca
['adaura', 'nsclc', 'sclc', 'aura ,(-laura)']
. nails the adaura discussion. highlights benefit by stage, esp del19. highlights no change to chemo indication as yet (agree!). mandates genotyping early nsclc. questions if we are curing-need more follow up; personalisation of risk #asco23 
Thoracic Oncologist @royalmarsdenNHS, Professor @ICR_London; Chair @BTOGorg; views are my own.